Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by a Subsidiary of Roivant Sciences

Avid Bioservices (NASDAQ:CDMO) a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that Enzyvant, a subsidiary of Roivant Sciences, has selected Avid as the commercial drug substance manufacturer for RVT-801, its recombinant human acid ceramidase enzyme replacement therapy being developed as a potential treatment for Farber disease.

As quoted in the press release:

“We are delighted to add Enzyvant to the growing list of companies that recognize Avid Bioservices’ ability to move critically important therapeutic products very rapidly into commercial manufacture,” said Roger Lias, Ph.D., president and chief executive officer of Avid Bioservices. “We take great pride in our more than 12-year track record of successfully manufacturing and releasing commercial biologic products for the US, EU and numerous other important international markets.”

Click here to read the full press release.